Recombinant Human IL-7 GMP Protein, CF GMP Best Seller
R&D Systems, part of Bio-Techne | Catalog # BT-007-GMP
Animal-Free.
New! Bypass reconstitution steps by using a liquid formulation of GMP-grade Recombinant Human IL-7. Find out more here.
Key Product Details
- Single use vials supplement 1L of T Cell Media (Cat # CCM038-GMP) to support T Cell Cultures in a G-Rex 100M bioreactor
- Liquid formulation minimizes reconstitution steps
- Lot-to-lot consistency
- Stringent guidelines for patient safety
- Scalability necessary to support successful therapeutics
- Learn more about manufacturing in our new GMP facility
- Test it in your process! Request a sample of GMP IL-7
Product Specifications
Source
E. coli-derived human IL-7 protein
Asp26-His177, with an N-terminal Met
Produced using non-animal reagents in an animal-free laboratory.
Manufactured and tested under cGMP guidelines.
Asp26-His177, with an N-terminal Met
Produced using non-animal reagents in an animal-free laboratory.
Manufactured and tested under cGMP guidelines.
Purity
>97%, by SDS-PAGE with quantitative densitometry by Coomassie® Blue Staining. The molecular weight
by mass spectrometry is 17507 Da ± 50 Da.
Endotoxin Level
<0.10 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Met-Asp26-(Cys)-Asp-Ile-Glu-Gly-Lys-Asp-Gly
Predicted Molecular Mass
17 kDa
SDS-PAGE
17 kDa, under reducing conditions
Activity
Measured in a cell proliferation assay using PHA-activated human peripheral blood lymphocytes (PBL). Yokota, T. et al. (1986) Proc. Natl. Acad. Sci. USA 83:5894.
The ED50 for this effect is 0.100-0.500 ng/mL.The specific activity of Recombinant Human IL-7 is >1.00 x 108 units/mg, which is calibrated against the human IL-7 reference standard (NIBSC code: 90/530).
The ED50 for this effect is 0.100-0.500 ng/mL.The specific activity of Recombinant Human IL-7 is >1.00 x 108 units/mg, which is calibrated against the human IL-7 reference standard (NIBSC code: 90/530).
Host Cell Protein
<0.5 ng per μg of protein when tested by ELISA.
Mycoplasma
Negative for Mycoplasma.
Host Cell DNA
<0.0015 ng per µg of protein when tested by PCR.
Scientific Data Images for Recombinant Human IL-7 GMP Protein, CF
Recombinant Human IL‑7 GMP Protein SEC-MALS.
Recombinant Human IL-7 GMP (Catalog # BT-007-GMP) has a molecular weight (MW) of 18.4 kDa as analyzed by SEC-MALS, suggesting that this protein is a monomer.
Recombinant Human IL-7 GMP Protein Bioactivity
GMP-grade Recombinant Human IL-7 (Catalog # BT-007-GMP) stimulates proliferation of PHA-activated human peripheral blood lymphocytes. The ED50 for this effect is 0.100-0.500 ng/mL. Three independent lots were tested for activity and plotted on the same graph to show lot-to-lot consistency of GMP IL-7.
Recombinant Human IL-7 GMP Protein SDS-Page
2 μg/lane of GMP-grade Recombinant Human IL-7 Protein (Catalog # BT-007-GMP) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing a single band at 17 kDa.
Formulation, Preparation and Storage
Lyophilized: BT-007-GMP
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. |
| Reconstitution | Reconstitute at 100-500 μg/mL in PBS. |
| Shipping | The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Liquid: BT-007-GMP/LQ
| Formulation | Supplied as a 0.2 μm filtered solution in PBS. |
| Shipping | The product is shipped with dry ice or equivalent. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: IL-7
IL-7 is produced by a wide variety of cells in primary and secondary lymphoid tissues, including stromal epithelial cells of the thymus, bone marrow, and intestines (1, 2, 5). Circulating IL-7 is limiting in healthy animals, but increases during lymphopenia (1, 6). IL-7 signals through a complex of the IL-7 Receptor alpha subunit (IL-7 R alpha, also known as CD127) with the common gamma chain ( gammac) (1). The gammac is also a subunit of the receptors for IL-2, -4, -9, -15, and -21 (1).
IL-7 R alpha is expressed on double negative (CD4-CD8-) and single positive (CD4+ or CD8+) naïve and memory T cells, but undergoes IL-7-mediated down‑regulation and shedding during antigen-driven T cell proliferation, and is absent on regulatory T cells (1, 2, 6-11). IL-7 contributes to the maintenance of all naïve and memory T cells, mainly by promoting expression of the anti-apoptotic protein Bcl-2 (9-11). It is required for optimal T cell-dendritic cell interaction (6). IL-7 is expressed early in B cell development prior to the appearance of surface IgM (1, 5, 9). In mouse, IL-7 activation of IL-7 R alpha is critical for both T cell and B cell lineage development, while in humans, it is required for T cell but not for B cell development (4, 9, 12, 13). However, IL-7 functions in both mouse and human pro-B cells to suppress premature Ig light chain recombination during proliferative growth (14, 15).
Like other common gamma-chain cytokines like IL-2 and IL-15,
IL-7 and its receptor, IL-7R, has been used in a variety of immunotherapy
applications, often in fluid tumors and in some instances of solid tumor models
(16). Sometimes use of recombinant IL-7 is preferential as current studies and
early clinical trials of cancer have found less severe toxicity or side effects
upon treatment with IL-7 in comparison to IL-15 or IL-2 (16).
In CAR-T cell therapies, enhanced expression and secretion
of human IL-7 and CCL19 have enhanced the ability of T cells to expand and
migrate in vitro (17). Engineered CAR T cells expressing IL-7 or a
constitutively active IL-7R results in increased efficacy of CAR T anti-tumor
effects (16, 18). IL-7 is also frequently used in combination with IL-15 as a
supplement in cell culture of CAR T cells to support their expansion (19).
Additionally, IL-7/IL-15 in the presence of cord blood-derived T cells helps to
maintain their early differentiation state (20).
Monoclonal antibodies against IL-7R or small
molecule inhibitors against the IL-7R signaling pathway are commonly used in
circumstances of autoimmune diseases to delay disease progression (16). Also due to its ability to stimulate both
adaptive and innate immune cells, treatment with IL-7 has shown improved
survival in patients with sepsis who are at risk of deadly secondary infections
(21), providing evidence for IL-7 applications beyond cancer immunotherapy.
References
- Sasson, S.C. et al. (2006) Curr. Drug Targets 7:1571.
- Barata, J.T. et al. (2006) Exp. Hematol. 34:1133.
- Goodwin, R.G. et al. (1990) Proc. Natl. Acad. Sci. USA 86:302.
- Namen, A.E. et al. (1988) Nature 333:571.
- Shalapour, S. et al. (2012) PLoS ONE 7: e31939.
- Saini, M. et al. (2009) Blood 113:5793.
- Park, J.H. et al. (2004) Immunity 21:289.
- Vranjkovic, A. et al. (2007) Int. Immunol. 19:1329.
- Sudo, T. et al. (1993) Proc. Natl. Acad. Sci. 90:9125.
- Seddon, B. et al. (2003) Nat. Immunol. 4:680.
- Schluns, K.S. et al. (2000) Nat. Immunol. 5:426.
- Peschon, J.J. et al. (1994) J. Exp. Med. 180:1955.
- Pribyl, J.A. and T.W. LeBien (1996) Proc. Natl. Acad. Sci. 93:10348.
- Johnson, K. et al. (2012) J. Immunol. 188:6084.
- Nodland, S.E. et al. (2011) Blood 118:2116.
- Wang, C. et al. (2022) Int. J. Mol. Sci. 23:10370.
- Pang, N. et al. (2021) J Hematol Oncol. 14:118.
- Li, L. et al. (2022) Sci Rep. 12:12506.
- Xu, Y. et al. (2014) Blood. 123:3750.
- Marton,C. et al. (2022) Cancer Gene Ther. 29:961.
- Winer, H. et al. (2022) Cytokine. 160:156049.
Long Name
Interleukin 7
Alternate Names
IL7, Lymphopoietin-1, PBGF
Gene Symbol
IL7
UniProt
Additional IL-7 Products
Product Documents for Recombinant Human IL-7 GMP Protein, CF
Manufacturing Specifications
GMP ProteinsR&D Systems, a Bio-Techne Brand's GMP proteins are produced according to relevant sections of the following documents: USP Chapter 1043, Ancillary Materials for Cell, Gene and Tissue-Engineered Products and Eu. Ph. 5.2.12, Raw Materials of Biological Origin for the Production of Cell-based and Gene Therapy Medicinal Products.
R&D Systems' quality focus includes:
- Manufactured and tested under an ISO 9001:2015 and ISO 13485:2016 certified quality system
- Documented processes and QA control of documentation and process changes
- Personnel training programs
- Raw material testing and vendor qualification/monitoring
- Fully validated equipment, processes and test methods
- Equipment calibration schedules using a computerized calibration program
- Facility maintenance, safety programs and pest control
- Material review process for variances
- Monitoring of stability over product shelf-life
R&D Systems strives to provide our customers with the analytical characteristics of each product so that customers may determine whether our products are appropriate for their research. The Certificate of Analysis provided contains the following lot specific information:
- N-terminal amino acid analysis, SDS-PAGE analysis, and endotoxin level (as determined by LAL assay) performed on each bulk QC lot, not on individual bottlings of each QC lot
- Post-bottling lot-specific bioassay results (compliance with an established range) and results of microbial testing according to USP <71>
- Host Cell Protein testing performed by ELISA
- Mycoplasma testing by ribosomal RNA hybridization assay
Additional testing and documentation requested by the customer can be arranged at an additional cost.
Production records and facilities are available for examination by appropriate personnel on-site at R&D Systems.
R&D Systems sells GMP grade products for preclinical or clinical ex vivo cell therapy applications. They are not for in vivo use. Please read the following End User Terms prior to using this product.
Animal-Free Manufacturing Conditions
Our dedicated controlled-access animal-free laboratories ensure that at no point in production are the products exposed to potential contamination by animal components or byproducts. Every stage of manufacturing is conducted in compliance with R&D Systems' stringent Standard Operating Procedures (SOPs). Production and purification procedures use equipment and media that are confirmed animal-free.
Production
- All molecular biology procedures use animal-free media and dedicated labware.
- Dedicated fermentors are utilized in committed animal-free areas.
- Protein purification columns are animal-free.
- Bulk proteins are filtered using animal-free filters.
- Purified proteins are stored in animal-free containers in a dedicated cold storage room.
Quality Assurance
- Low Endotoxin Level.
- No impairment of biological activity.
- High quality product obtained under stringent conditions.
Product Specific Notices for Recombinant Human IL-7 GMP Protein, CF
END USER TERMS OF USE OF PRODUCT
The following terms are offered to you upon your acceptance of these End User Terms of Use of Product. By using this product, you indicate your acknowledgment and agreement to these End User Terms of Use of Product. If you do not agree to be bound by and comply with all of the provisions of these End User Terms of Use of Product, you should contact your supplier of the product and make arrangements to return the product.
We suggest you print and retain a copy of these End User Terms of Use of Product for your records.
The End User is aware that R&D Systems, Inc. sells GMP products for preclinical or clinical ex vivo use and not for in vivo use. The End User further agrees, as a condition of the sale of R&D Systems' GMP products that: a) the End User will not use this GMP Product in any procedure wherein the product may be directly or indirectly administered to humans, unless the End User has obtained, or prior to their use will have obtained, an Investigational New Drug (IND) exemption from the FDA and will use the product only in accordance with the protocols of such IND and of the Institutional Review Board overseeing the proposed research, or b) the End User will use the products outside of the United States in accordance with the protocols of research approved by the Institutional Review Board or authorized ethics committee and regulatory agencies to which the End User is subject to in their territory.
R&D Systems, Inc. has the right, at its sole discretion, to modify, add or remove any terms or conditions of these End User Terms of Use without notice or liability to you. Any changes to these End User Terms of Use are effective immediately following the printing of such changes on this product insert. The most recent version of these End User Terms of Use of Product may be found at: RnDSystems.com/Legal.
You agree to review these End User Terms of Use of Product to ensure any subsequent use by you of R&D Systems' GMP Products following changes to these End User Terms of Use of Product constitutes your acceptance of all such changes.
TERMS AND CONDITIONS
The following limitation applies to R&D Systems' warranty and liability for damages: All products are warranted to meet R&D Systems' published specifications when used under normal laboratory conditions.
R&D SYSTEMS DOES NOT MAKE ANY OTHER WARRANTY OR REPRESENTATION WHATSOEVER, WHETHER EXPRESS OR IMPLIED, WITH RESPECT TO ITS PRODUCTS. IN PARTICULAR, R&D SYSTEMS DOES NOT MAKE ANY WARRANTY OF SUITABILITY, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR ANY PARTICULAR PURPOSE.
NOTWITHSTANDING ANY OTHER PROVISIONS OF THESE TERMS AND/OR ANY OTHER AGREEMENT BETWEEN R&D SYSTEMS AND PURCHASER FOR THE PURCHASE OF THE PRODUCTS, R&D SYSTEMS' TOTAL LIABILITY TO PURCHASER ARISING FROM OR IN RELATION TO THESE TERMS, AN AGREEMENT BETWEEN THE PARTIES OR THE PRODUCTS, WHETHER ARISING IN CONTRACT, TORT OR OTHERWISE SHALL BE LIMITED TO THE TOTAL AMOUNT PAID BY PURCHASER TO R&D SYSTEMS FOR THE APPLICABLE PRODUCTS. IN NO EVENT WILL R&D SYSTEMS BE LIABLE FOR THE COST OF PROCUREMENT OF SUBSTITUTE GOODS.
Full details of R&D Systems' Terms and Conditions of Sale can be found online at: RnDSystems.com/Legal.
For preclinical, or clinical ex vivo use
Loading...
Loading...
Loading...